Cover Image

Vironova AB:產品平台分析

Vironova AB - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 253691
出版日期 內容資訊 英文 19 Pages
Back to Top
Vironova AB:產品平台分析 Vironova AB - Product Pipeline Review - 2014
出版日期: 2014年06月10日 內容資訊: 英文 19 Pages



Vironova AB,是把病毒性疾病的預防及治療作為目的開發抗病毒藥物及病毒鑑定產品的生物科技企業。

本報告提供Vironova AB的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Vironova AB的基本資料

Vironova AB概要

  • 主要資訊
  • 企業資料

Vironova AB:R&D概要

  • 主要的治療範圍

Vironova AB:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Vironova AB:開發中產品概況

  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

Vironova AB:藥物簡介

  • Drug to Inhibit Capsid Protein for HIV-1 Infection
  • A型流感感染疾病的小分子
  • VN-180

Vironova AB:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Vironova AB:最近的開發平台趨勢

Vironova AB:總公司和子公司的所在地


Product Code: GMDHC05029CDB

Global Markets Direct's, 'Vironova AB - Product Pipeline Review - 2014', provides an overview of the Vironova AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vironova AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Vironova AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vironova AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vironova AB's pipeline products

Reasons to buy

  • Evaluate Vironova AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vironova AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vironova AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vironova AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vironova AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vironova AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vironova AB Snapshot
    • Vironova AB Overview
    • Key Information
    • Key Facts
  • Vironova AB - Research and Development Overview
    • Key Therapeutic Areas
  • Vironova AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Vironova AB - Pipeline Products Glance
    • Vironova AB - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Vironova AB - Drug Profiles
    • Drug to Inhibit Capsid Protein for HIV-1 Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Influenza A Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VN-180
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vironova AB - Pipeline Analysis
  • Vironova AB - Pipeline Products by Target
  • Vironova AB - Pipeline Products by Molecule Type
  • Vironova AB - Pipeline Products by Mechanism of Action
  • Vironova AB - Recent Pipeline Updates
  • Vironova AB - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vironova AB, Key Information
  • Vironova AB, Key Facts
  • Vironova AB - Pipeline by Indication, 2014
  • Vironova AB - Pipeline by Stage of Development, 2014
  • Vironova AB - Monotherapy Products in Pipeline, 2014
  • Vironova AB - Discovery, 2014
  • Vironova AB - Pipeline by Target, 2014
  • Vironova AB - Pipeline by Molecule Type, 2014
  • Vironova AB - Pipeline Products by Mechanism of Action, 2014
  • Vironova AB - Recent Pipeline Updates, 2014
  • Vironova AB, Subsidiaries

List of Figures

  • Vironova AB - Pipeline by Top 10 Indication, 2014
Back to Top